

Semi-Open Magnetocardiography Platform

Rethinking Diagnostics in Cardiology with Quantum Sensing & AI

Our Brand-New Semi-Open MCG Platform Strategy is the Game Changer in the (preventive) diagnostics of heart diseases. With highest precision, the procedure is contactless/non-invasive, free of side effects and takes only one minute to evaluate the patient's heart.

Our Vision For the Next 10 Years is to disrupt the future of precision medicine and drug development (beyond cardiology). This is how we will create enormous benefits for millions of patients every year worldwide.

Technology: Heart magnetic field measurements down to femto Tesla (10^{-15} T) with a previously unthinkable information content by using quantum sensors ([SQUID](#)).

Achievements by 2022:

- ... >8,000 long-term MCG data sets from 20 years
- ... Global technology & clinical network
- ... Bmp's world novelties in 2022:
 - ... **Magnetoionography** measures intracellular ion currents; now cardiologists and drug developers can look directly inside patients' heart cells!
 - ... **Diagnosis of Myocarditis** determined with a [specificity of 95%](#); [paper Charité](#)
 - ... **Sudden Cardiac Death Prognosis** over 6.5 years determined with a [sensitivity of 90.9%](#) based on long-term datasets of [Yonsei University](#) Korea.



Economic Potential

MCG will be a new gold standard in diagnostics. This means tens of thousands of platforms worldwide, just like MRI and CT.

Investment 2010-2022

13 m
(Private capital only)



Current Investment Round

Jun 2023 Series A: 12 m

<https://www.biomagnetik.com>